Information required for submission of Letter of Interest (LOI) to Medicines for Malaria Venture's 12th Call for Proposals for Malaria Drug Discovery Projects

Deadline for receipt in MMV office: 12 noon (CET) March 14th, 2014

Please read the instructions carefully. Submissions should be completed on 3 pages of A4. MMV will only receive submissions electronically; please see the accompanying templates and contact details at the end of this document.

There are two stages to the process of seeking funding of a project through the Medicines for Malaria Venture.

The first stage is a concise 3 page LOI outlining the project using the guidelines and templates provided. These letters will be competitively assessed by MMV and MMV’s Expert Scientific Advisory Committee (ESAC). A short-list of projects will then be invited for the submission of a more detailed proposal, which will be presented and discussed at the MMV offices in Geneva, in a face-to-face meeting (later in 2014) with MMV and MMV ESAC. Experience has shown that MMV funding is highly competitive and it is in your interest to present all relevant data as completely and as concisely as possible. Some guidelines on this are provided below.

Please note: If you have several approaches or potential projects that you wish to propose for funding, then each approach should be submitted as a separate project application. Please remember when preparing the application that MMV and the MMV ESAC is already familiar with the key issues of malaria, malaria chemotherapy and the need for antimalarial drugs. So please focus on key information and data. Your proposal should restrict itself to details placed in the context of drug discovery.

MMV has highlighted three key areas necessary for the control and eradication of malaria. They are:

1. **Compounds addressing the key priorities of the malaria eradication agenda**
   New families of molecules in the hit-to-lead and lead optimization phases are sought that:
   - kill or reactivate hypnozoites for use as part of a *P. vivax* radical cure;
   - have dual activity against asexual and sexual stages for treatment and transmission blocking;
   - are novel and without G6PD deficiency liabilities.

2. **Assays addressing liver stage vivax**
   - Novel, robust and validated *in vitro* or *in vivo* models of vivax liver stages are sought that are suitable for immediate compound testing. See the website for specific details.

3. **Asexual liver and blood stages**
   Novel chemical series that have one or more of the following key features:
   - A novel mechanism of action;
• A long half-life (ideally >10h in rodents) and confirmed in vivo efficacy;
• For advanced series, we are seeking compounds with, ideally, a predicted human half-life >100h and a predicted single human dose <1g.

The highest priority area is covered by the first two points: robust assays to measure and compounds to block relapses in P. vivax. A summary of all the MMV Target Candidate Profiles that explain the thinking, strategy and criteria for all our molecules can be found in the following paper: http://www.malariajournal.com/content/12/1/187

Our ultimate ambition is to deliver treatments that are completed with a single dose so as to ensure patient compliance, have a low cost of goods and which are likely to have activity against all known resistant strains, including those resistant to artemisinin.

The following information will assist you in preparing a focused application.

The 1st page of your application should outline:
• Project title
• Contact details of Principal Investigator, and partners with areas of responsibility of within the project and a succinct description of their professional expertise and contribution to the team.
• Overall goals of the project and the Target Candidate Profile focus
• Proposal Phase – to clarify the position of the proposal within the drug development continuum (delete as appropriate)

The 2nd page of your application should include:
• Scientific basis for the project and justification vs. the call for proposals criteria e.g.
  ⇒ Biology rationale
  ⇒ Chemistry rationale
  ⇒ Evidence of site capacity to run an anti-relapse vivax model (as appropriate)
  ⇒ Comparative advantages of approach (and compounds) over existing drugs and other approaches
• Project status:
  Give a clear account what has been achieved to date giving the latest full data and information.
  ⇒ Identify where the project is in relation to its goals and include any key results
  ⇒ Include pharmacokinetic and safety data when available
  ⇒ Clearly state activities of any lead compounds
    (a) in vitro against enzyme / molecular target e.g., IC₅₀ / Ki
    (b) in culture against parasite strains e.g. EC₅₀ along with mammalian cytotoxicity data;
    (c) in animal models e.g., ED₅₀, indicating route of application and precise model.
  ⇒ Chemical structures of lead compounds should be provided along with medicinal chemistry comments; as with all other information these will be treated confidentially.
  ⇒ Please give a full overview of any anti-relapse model, in particular in relation to the assay criteria. Please refer to the document “criteria for P. vivax” on MMV’s website.
The 3rd page of your application should include:

• Highlight the critical issues and explain the mitigation strategy
  ⇒ Give a summary of the medicinal chemistry plan specifically focusing on how the critical issues will be solved whilst maintaining the attractive properties
  ⇒ Identify gaps in knowledge or a bottleneck that need to be addressed to validate the biological approach, compound or clinical site
  ⇒ Give specific timed milestones for the progression of the project towards the final goal
  ⇒ Outline project approach and methodologies to be used

• Likely resource requirements and how these would be allocated to: project partners, consumables, etc.
  ⇒ Include budget for year 1.
  ⇒ Costs may be approximate at this stage.
  ⇒ Please note that MMV has a zero indirect cost policy.

• Maximum 3 literature references if any.

If accepted, the project will be integrated into the MMV portfolio as soon as a legal agreement is reached between MMV and the relevant parties. As part of the MMV portfolio, we will strive to aid movement of the project toward drug development and registration for fast access to the markets in developing countries.

SUBMISSION CONTACT DETAILS:

Deadline for receipt in MMV office: 12 noon CET March 14th, 2014
Send your 3 page letter of interest, electronically to: proposals@mmv.org